Al Gianchetti has more than 25 years of drug development and commercialization experience, including over 10 years in the cardiovascular/metabolic therapeutic area. He has held executive level roles at GSK and additional leadership roles with small biotech and specialty pharma companies including Vanda Pharmaceutics. Mr. Gianchetti has extensive experience in both commercial strategy/operations and R&D including seven Phase III programs, over 10 Phase I/II programs and several product launches.

• 

  Chief Executive Officer (CEO) in XyloCor Therapeutics

  Gene therapy for advanced coronary artery disease